CMS Transparency in Coverage: What Machine-Readable Files Reveal About Your Pharmacy Benefit
The $146 PMPM Surprise: What Your Files Tell Competitors (and You)
Last quarter, I sat across from a CFO who was sure her company’s pharmacy plan was “average cost.” Yet her data showed a $146 per member per month pharmacy spend, well above the $120 national benchmark for her 900-life manufacturing group. When I pulled her plan’s machine-readable file, required under the CMS Transparency in Coverage (TiC) rules, the numbers matched up, and they also revealed two things: her PBM contract rates for specialty drugs were 8% higher than a peer down the street, and a handful of off-formulary claims accounted for a big chunk of waste. The TiC files didn’t create her overspending, but they exposed it to anyone willing to dig through a 400MB JSON file.
A few years ago, pharmacy pricing was a black box. Today, employers, consultants, and even competing brokers can download published rates and start benchmarking. This is changing the way mid-market employers negotiate, manage, and defend their pharmacy benefit strategies. But the flood of raw data brings confusion as well as opportunity.
What’s Actually in Your Pharmacy Machine-Readable File?
The CMS TiC rule went live July 1, 2022, forcing group health plans and carriers to post massive, machine-readable files (MRFs) online. For pharmacy, these files list the negotiated rates for every covered prescription drug at every in-network pharmacy, along with historic prices paid for those same claims. The intent was to expose price variation and help plan sponsors shop smarter. Instead, many benefits leaders opening these files are hit with information overload.
Here’s what you’ll find, if you can get the file to open:
- Drug names and National Drug Codes (NDCs)
- Plan’s negotiated ingredient cost (often the AWP minus X% or MAC price)
- Dispensing fees and administrative fees
- Pharmacy names and locations
- Historic allowed amounts for each claim
The nuance is in the details. Your file may show that generic amlodipine is paid at $0.25 per pill at CVS but $0.12 at Walmart. Or that your Humira negotiated rate is $6,700 per fill, while a peer’s plan shows $4,100 for a biosimilar like Hadlima. These are not “guaranteed” net costs, rebates and copay programs complicate the final paid claim, but it’s the first time this much pricing data has been so public. For a sense of scale, check out RxPBM.ai, which aggregates PBM contract intelligence from these files.
For benefits teams, the challenge is not just technical. The files are big and messy, and you’ll need a consultant or a data-savvy broker to pull out the trends that matter. But if your competition is using this data to negotiate sharper PBM terms, you can’t afford to ignore it.
What Can You Actually Learn From Your Plan’s Data?
The goldmine, and the minefield, comes in benchmarking your pharmacy benefit. Suppose you’re a 400-employee services firm with a $1.3M annual pharmacy spend. Pulling the MRF, you see your average generic fill is paid at $17.80, but a peer’s plan across town posts just $12.90. You dig deeper and realize your PBM is using a “traditional” contract with spread pricing, while the peer is on a pass-through arrangement with an independent PBM like Capital Rx or Navitus. That $5 per fill gap translates to more than $40,000 a year for your plan.
Machine-readable files also flag outlier claims. On a recent review, I saw a client paying $34,000 annually for Humira when biosimilars were available at a 55% discount. The file revealed the PBM’s biosimilar pricing was published, but the plan’s clinical edits let the original through. After a formulary tweak, the employer saved $22,000 per member per year, without disrupting most employees.
The public file can’t tell you everything. Rebates, copay assistance (like RxSaver.ai for couponing), and stop-loss carve-outs all affect net cost. But if your plan’s paid rates on high-cost drugs are an outlier, it’s a starting point for negotiation. Pharmacy benefit consultants use these published rates to pressure PBMs during renewals and RFPs, and you should expect them to bring your competitors’ rates into the discussion.
Practical Pitfalls: When Transparency Hurts More Than It Helps
Transparency is a two-edged sword. Sometimes employers misread the TiC files and chase “savings” that evaporate after rebates or cause employee disruption. I’ve seen HR teams push for a new PBM with lower published rates, only to discover that member disruption led to a spike in appeals, or that the new network excluded local independents critical to their workforce.
Another trap: fixating on generic rates or lowest AWP discount, while ignoring mix-of-business and drug utilization trends. A plan with a 91.4% generic dispensing rate could still have 70% of its total spend in specialty drugs, driving up PMPM regardless of retail generic costs. Behavioral interventions, like moving GLP-1 (Ozempic, Wegovy) use to evidence-based criteria, often yield more impact than shaving a few points off multi-source generic pricing. For specialty, using the machine-readable file to compare biosimilar pricing across PBMs (see RxInfo.ai for real drug pricing data) can lead to more meaningful negotiations.
There’s also a compliance angle. Employers are responsible under ERISA for selecting and monitoring benefits providers with “prudence.” If your file shows you’re paying 20% above market for high-volume generics, or if your PBM’s contract terms are less competitive, you may need to document why you’re staying put, or be ready to explain it if a participant or attorney asks. Get your ERISA counsel involved if you’re worried about fiduciary exposure, especially for large plans or those going self-funded.
Turning Data into Better Pharmacy Decisions
Machine-readable files won’t solve your pharmacy strategy overnight. But they do arm you, along with your consultants, brokers, and even stop-loss partners, with more visibility than ever before. The best case I’ve seen: a 1,200-life hospital system used its TiC files to push for biosimilar Humira adoption, saving $280,000 in year one, then reinvested those savings into a support program for GLP-1 adherence.
Practical next steps? Don’t try to parse these files solo. Bring in a pharmacy consultant who can benchmark your published rates, flag network gaps, and run disruption analyses before you make changes. Use the data to pressure PBMs for sharper contract terms, particularly on specialty drugs and high-volume generics. And keep an eye on utilization, not just unit cost, since drug mix increasingly drives pharmacy inflation. If you want to keep up with the latest drug launches and pricing shockwaves, resources like RxNews.ai and ClinicalRx.ai can help you spot trends before they hit your bottom line.
In this new era, your competitors, and your employees, can see more of your pharmacy spend than ever before. Make sure you can explain what’s in your machine-readable file and, more importantly, what you’re doing about it.